Health iQ were named inaugural winners of The Inspiration Award at last week’s PM Society Digital Awards 2017.
The prestigious awards, held in London every year, are the biggest, dedicated, digital-focused awards scheme in the healthcare arena.
As well as 15 award categories, judges were asked to highlight any entries that stood out as inspirational and which the judges felt set great examples to others in the industry.
Health iQ and Sanofi Genzyme alongside host, Russell Kane, and judge Paul Jacobs of LEO Pharma
The Inspiration Award was presented to Health iQ, and Sanofi Genzyme who commissioned the project, for a groundbreaking approach to early diagnosis of children with MPS I - an ultra-orphan condition. The project combined analysis of disease registries, clinician interviews and real world data science with digital medical communications to produce a novel approach that delivered early diagnosis rates 3 times higher than before.
Health iQ's CEO, Jilani Gulam, accepted the award and commented:
“Winning the Inspiration Award is an amazing achievement since it is validation from peers, customers and competitors that we have raised the bar, improved standards and really benefitted patient care. This award is a celebration of what the Industry should be doing more of and I am immensely proud that in some way we have led the way forward”.
Paul Jacobs, of LEO Pharma, was part of the judging panel for the category and presented the award on the night:
"This innovative project used a combination of real-world evidence, clinical insight and medical communications to increase awareness around this ultra-rare, life-limiting condition while safeguarding patient data. The results are already impressive, and shows how innovative thinking can be applied. This project is an example that I think needs to be learnt from within our industry, perhaps as a model for use in other rare diseases”.
John Ivory, Head of Rare Diseases, UK & Ireland and Country Head Sanofi Genzyme, Ireland added:
“Winning this Inspiration Award is a fantastic endorsement of the innovative work undertaken within the Sanofi Genzyme Rare Disease team. Patients with ultra-orphan disorders can face huge challenges over many years before getting a diagnosis. This MPS I project is highly transferrable across other ultra-orphan disorders and highlights our commitment to the rare disease community”.
Notes to editors
Health iQ is a privately-owned company based in London specializing in insight into real world healthcare data based on an outstanding heritage of working in the NHS. It now works with more than half of the top 100 global Life Science firms.
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology.
Founded as Genzyme in Boston in 1981, it became part of Sanofi in 2011 and has retained its dedication to patients which extends beyond the development of products.
The PM Society was established over 40 years ago as a not-for-profit organisation to serve the needs of the pharmaceutical industry and its service agencies. It currently has over 230 UK companies as members, including pharma and biotech companies on the industry side and PR, Advertising, Medical Communications, Digital and many other kinds of service company on the agency side.
The PM Society Digital Awards took place on 6th September 2017. More information and full results are available at https://pmsociety.org.uk/awards/digital/2017/index